Literature DB >> 22791079

Biotin ameliorates muscle cramps of hemodialysis patients: a prospective trial.

Shiro Oguma1, Itiro Ando, Takuo Hirose, Kazuhito Totsune, Hiroshi Sekino, Hiroshi Sato, Yutaka Imai, Masako Fujiwara.   

Abstract

Patients with renal failure undergoing hemodialysis often have muscle cramps during and after the dialysis therapy. Muscle cramps are defined as the sudden onset of a prolonged involuntary muscle contraction accompanied with severe pain, resulting in early termination of a HD session and inadequate dialysis. The etiology of the cramps is unknown and effective anti-cramp medicine is not available. We have hypothesized that water-soluble vitamins are deficient in HD patients. Accordingly, we administrated biotin to 14 patients who had frequent muscle cramps during HD sessions. Oral administration of 1 mg/day biotin promptly reduced the onset and the severity of cramps in 12 patients both during and after HD. Then, the plasma biotin levels were measured by an enzyme-linked immunosorbent assay method (ELISA) in HD patients, including 14 patients with cramps and 13 patients without cramps, and 11 healthy volunteers. Plasma biotin levels were elevated in 27 HD patients at baseline compared with healthy volunteers [451 (377 - 649) vs. 224 (148 - 308) ng/l, median (lower-upper quartiles); p < 0.0001]. Unexpectedly, among the 14 cramp patients, the biotin levels were significantly higher in biotin-ineffective 7 patients than biotin-effective 7 patients [1,064 (710 - 1,187) vs. 445 (359 - 476) ng/l; p < 0.001]. Thus, the biotins measured by ELISA may consist of not only intact biotin but also its metabolites that do not function as a vitamin. In conclusion, biotin administration is one choice to relieve HD patients from muscle cramps regardless of their elevated plasma biotin levels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22791079     DOI: 10.1620/tjem.227.217

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  5 in total

1.  Citric Acid-Containing Dialysate and Survival Rate in the Dialysis Outcomes and Practice Patterns Study.

Authors:  Pablo Ureña-Torres; Brian Bieber; Fitsum Guebre-Egziabher; Rim Ossman; Michel Jadoul; Masaaki Inaba; Bruce M Robinson; Friedrich Port; Christian Jacquelinet; Christian Combe
Journal:  Kidney360       Date:  2021-02-04

2.  Conceptual Framework for Patient-Reported Outcome Measures in Clinical Trials of Skeletal Muscle Cramping Experienced in Dialysis: A Kidney Health Initiative Workgroup Report.

Authors:  Michelle M Richardson; Amanda Grandinetti; Tandrea S Hilliard-Boone; Kenneth R Wilund; Rebecca Wingard; Wendy L St Peter; Dilani Logan; Francesca Tentori; San Keller; Melissa West; Eduardo Lacson
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-15       Impact factor: 10.614

Review 3.  A Higher Concentration of Dialysate Magnesium to Reduce the Frequency of Muscle Cramps: A Narrative Review.

Authors:  Akshay Varghese; Eduardo Lacson; Jessica M Sontrop; Rey R Acedillo; Ahmed A Al-Jaishi; Sierra Anderson; Amit Bagga; Katie L Bain; Laura L Bennett; Clara Bohm; Pierre A Brown; Christopher T Chan; Brenden Cote; Varun Dev; Bonnie Field; Claire Harris; Shasikara Kalatharan; Mercedeh Kiaii; Amber O Molnar; Matthew J Oliver; Malvinder S Parmar; Melissa Schorr; Nikhil Shah; Samuel A Silver; D Michael Smith; Manish M Sood; Irina St Louis; Karthik K Tennankore; Stephanie Thompson; Marcello Tonelli; Hans Vorster; Blair Waldvogel; James Zacharias; Amit X Garg
Journal:  Can J Kidney Health Dis       Date:  2020-10-22

4.  The effect of acupressure on muscle cramps in patients undergoing hemodialysis.

Authors:  Kolsoom Mohmadi; Nahid Shahgholian; Mahboubeh Valiani; Hossein Mardanparvar
Journal:  Iran J Nurs Midwifery Res       Date:  2016 Nov-Dec

Review 5.  Epidemiology of haemodialysis outcomes.

Authors:  Aminu K Bello; Ikechi G Okpechi; Mohamed A Osman; Yeoungjee Cho; Htay Htay; Vivekanand Jha; Marina Wainstein; David W Johnson
Journal:  Nat Rev Nephrol       Date:  2022-02-22       Impact factor: 42.439

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.